Octanorm

Phase 3Biologic

Octapharma

Octanorm is one of 59 biologic programs targeting Immunodeficiency Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunodeficiency DiseaseActive, not recruiting

DermatomyositisActive, not recruiting

Immunodeficiency DiseasePhase 3

Active, not recruiting

DermatomyositisPhase 3

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Dermatomyositis

#DrugCompanyPhaseTrials

Xeljanz

PPrism Pharmaceuticals

Approved

2 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Olumiant

2 4

Stelara

Johnson & Johnson

Phase 3

1 5

JAK Inhibitor

FFred Hutchinson Cancer Center

Approved

1 6

Proleukin

IIovance Biotherapeutics, Inc.

Otezla

2 8

Actemra

Roche

Phase 2

1 9

Ultomiris

AstraZeneca

Phase 2

1 10

Jakafi

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency Disease2 trials

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Completed· Octapharma logo

Octapharma·Phase 3·NCT03988426·25 enrolled

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Completed· Octapharma logo

Octapharma·Phase 3·NCT03907241·27 enrolled

Dermatomyositis1 trial

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Terminated· Octapharma logo

Octapharma·Phase 3·NCT03686969·1 enrolled

Unspecified1 trial

Study of Octanorm Subcutaneous IG in Patients With PID

Completed· Octapharma logo

Octapharma·Phase 3·NCT01888484·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Octanorm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octanorm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octanorm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Octanorm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency Disease2 trials

Dermatomyositis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News